---
title: "Janux Therapeutics Announces Departure of Chief Strategy Officer"
description: "Janux Therapeutics Inc (JANX) announced the departure of Byron Robinson, Ph.D., as Chief Strategy Officer, effective September 18, 2025, classified as a termination without ‘Cause’. The current analys"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/258150947.md"
published_at: "2025-09-19T21:30:41.000Z"
---

# Janux Therapeutics Announces Departure of Chief Strategy Officer

> Janux Therapeutics Inc (JANX) announced the departure of Byron Robinson, Ph.D., as Chief Strategy Officer, effective September 18, 2025, classified as a termination without ‘Cause’. The current analyst rating for JANX stock is a Hold with a price target of $24.50. Spark’s AI Analyst rates JANX as Neutral, citing strong revenue growth but ongoing profitability challenges. The stock has a market cap of $1.41B and an average trading volume of 772,841.

The latest update is out from Janux Therapeutics Inc ( (JANX) ).

Byron Robinson, Ph.D., previously a named executive officer of Janux Therapeutics, Inc., ceased to serve as Chief Strategy Officer and departed from the company effective September 18, 2025. His departure was classified as a termination without ‘Cause’ according to the company’s Change in Control and Severance Benefit Plan.

The most recent analyst rating on (JANX) stock is a Hold with a $24.50 price target. To see the full list of analyst forecasts on Janux Therapeutics Inc stock, see the JANX Stock Forecast page.

**Spark’s Take on JANX Stock**

According to Spark, TipRanks’ AI Analyst, JANX is a Neutral.

Janux Therapeutics Inc’s stock score is primarily influenced by its strong revenue growth and solid balance sheet, but is offset by ongoing profitability challenges and negative cash flows from operations. Technical indicators suggest a neutral market sentiment, while valuation metrics highlight concerns due to negative earnings and lack of dividends.

To see Spark’s full report on JANX stock, click here.

**More about Janux Therapeutics Inc**

**Average Trading Volume:** 772,841

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $1.41B

For an in-depth examination of JANX stock, go to TipRanks’ Overview page.

### Related Stocks

- [JANX.US - Janux Therapeutics](https://longbridge.com/en/quote/JANX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Janux Therapeutics (NASDAQ:JANX) VP Maria Dobek Sells 1,462 Shares | Janux Therapeutics VP Maria Dobek sold 1,462 shares at $13.73 each, totaling $20,073.26, representing an 8.68% decrease  | [Link](https://longbridge.com/en/news/271371833.md) |
| Janux Therapeutics' (JANX) Outperform Rating Reaffirmed at Wedbush | Wedbush reaffirmed its "outperform" rating for Janux Therapeutics (NASDAQ:JANX) with a revised target price of $45.00, d | [Link](https://longbridge.com/en/news/268530722.md) |
| TD Cowen Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX) | TD Cowen analyst Marc Frahm maintained a Buy rating on Janux Therapeutics Inc, with shares closing at $14.31. Frahm, a 5 | [Link](https://longbridge.com/en/news/270816751.md) |
| Janux Therapeutics (NASDAQ:JANX) Reaches New 52-Week Low  - What's Next? | Janux Therapeutics (NASDAQ:JANX) hit a new 52-week low at $15.49. Analysts have mixed price targets, with Barclays at $4 | [Link](https://longbridge.com/en/news/269251820.md) |
| Cantor Fitzgerald Reaffirms Their Buy Rating on Janux Therapeutics Inc (JANX) | Cantor Fitzgerald has reaffirmed a Buy rating on Janux Therapeutics Inc (JANX) with a price target of $200. Analyst Josh | [Link](https://longbridge.com/en/news/264899624.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.